Multilayer drug delivery device with nano-sized copolymer matrix sheet

The multilayer drug delivery device with nano-sized copolymer matrix sheets and a rate control membrane addresses bioavailability issues by providing controlled, sustained, and sequential drug release, enhancing encapsulation and reducing systemic toxicity.

JP3258294UActive Publication Date: 2026-11-19ロウダ·エム·オカシャ +7
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2026003165U
Authority / Receiving Office
JP · JP
Patent Type
Utility models
Current Assignee / Owner
Filing Date
2026-09-10
Publication Date
2026-11-19
Estimated Expiration
2036-09-10

AI Technical Summary

Technical Problem

Conventional drug delivery systems suffer from low bioavailability, rapid clearance, burst release, and the need for repeated administration due to the lack of nano-sized copolymer matrix sheets, leading to unpredictable release profiles and insufficient cellular uptake.

Method used

A multilayer drug delivery device incorporating nano-sized copolymer matrix sheets made of PLGA-PEG with an intermediate barrier layer and a rate control membrane, enabling controlled, sustained, and sequential release through diffusion and erosion mechanisms.

Benefits of technology

The device achieves sustained drug release over 24-168 hours with reduced burst release, encapsulation efficiency exceeding 85%, and near-zero-order kinetics, suitable for transdermal, implantable, and mucosal applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0003258294000001_ABST
    Figure 0003258294000001_ABST
Patent Text Reader

Abstract

This invention provides a multilayer drug delivery device that achieves continuous and sequential drug release over a period of 24 to 168 hours while reducing burst release compared to a single-layer configuration. [Solution] The device comprises a backing layer 101, a first nano-sized copolymer matrix sheet 102 made of poly(lactic acid-glycolic acid copolymer)-block-polyethylene glycol copolymer with a thickness of 50 to 500 nanometers and containing therapeutic agent particles 106, an intermediate barrier layer 103, a second nano-sized copolymer matrix sheet 104 containing therapeutic agent particles 106, a rate control membrane 105 made of ethyl cellulose and polyvinylpyrrolidone containing micropores 107, and an adhesive layer 108. The rate control membrane 105 contains micropores 107 formed by the dissolution of polyvinylpyrrolidone domains upon contact with biological fluids.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present disclosure relates generally to drug delivery devices for pharmaceuticals, and more particularly to a multilayer drug delivery device configured to achieve controlled, sustained and sequential release of one or more therapeutic agents through programmable degradation of biodegradable copolymer layers incorporated as nano-sized matrix sheets within a layered structure device. BACKGROUND ART

[0002] Conventional drug delivery approaches, including oral tablets, capsules and injections, often suffer from problems such as low bioavailability, rapid clearance, burst release phenomenon, and the need for repeated administration to maintain therapeutic plasma concentrations. These limitations lead to reduced patient compliance, increased side effects, and variability in therapeutic outcomes.

[0003] Multilayer drug delivery structures have emerged as a strategy to achieve temporal and spatial control of drug release. By incorporating a plurality of distinct layers each with different compositions, porosity and degradation properties, it becomes possible to design devices that release drugs in a predetermined sequence or in a sustained manner. However, existing multilayer configurations often rely on conventional polymeric materials that lack the nanoscale structural refinement required to precisely control release kinetics. Specifically, the absence of nano-sized copolymer matrix components in conventional multilayer designs limits the achievable resolution of drug release modulation, leading to unpredictable release profiles and insufficient cellular uptake efficiency.

[0004] Copolymer-based nanostructure matrices offer distinct advantages not found in homopolymer systems, including a tunable hydrophilic-hydrophobic balance, control of degradation rates by altering monomer ratios, improved mechanical flexibility, and superior drug encapsulation capabilities. Nano-sized copolymer sheets in the 50-500 nanometer thickness range provide a high surface area-to-volume ratio, facilitating uniform drug dispersion and predictable, controlled diffusion release. Despite these advantages, no prior art effectively combines multilayer device configurations with nano-sized copolymer matrix sheets to achieve programmable sequential drug release with improved bioavailability and reduced systemic toxicity. [Prior art documents] [Patent Documents]

[0005] [Patent Document 1] U.S. Patent No. 10864158 - Multilayer thin-film drug delivery device including microporous and nanoporous layers for controlled release of bioactive agents [Patent Document 2] U.S. Patent Application Publication No. 2012 / 0078204 - Transdermal drug delivery system including a multilayer adhesive matrix for modulating drug delivery profiles through the skin [Overview of the Initiative] [Problems that the invention aims to solve]

[0006] The prior art devices described above do not incorporate nano-sized copolymer matrix sheets having adjustable degradation profiles, nor do they provide a standalone multilayer device that enables independently programmable sequential drug release from individual copolymer layers. Patent Document 1 does not mention integrating multiple drug reservoirs within individual nano-sized copolymer layers for programming sequential release. Patent Document 2 relies on pressure-sensitive adhesive polymers and does not employ nano-sized copolymer matrix sheets or biodegradable copolymer structures for release via controlled degradation.

[0007] Therefore, there is a need for a device that can provide controlled, sustained, and sequential release of therapeutic agents through a multilayer structure incorporating nano-sized copolymer matrix sheets with programmable degradation properties, thereby overcoming the limitations of burst release and low bioavailability inherent in conventional drug delivery systems. [Means for solving the problem]

[0008] According to one aspect of the present disclosure, a multilayer drug delivery device is provided, comprising: a backing layer made of an impermeable biocompatible material; one or more nano-sized copolymer matrix sheets made of poly(lactic acid-glycolic acid copolymer)-block polyethylene glycol copolymer, having a thickness in the range of 50 to 500 nanometers, each encapsulating at least one therapeutic agent; one or more intermediate barrier layers disposed between adjacent nano-sized copolymer matrix sheets; a rate control membrane containing a blend of ethyl cellulose and polyvinylpyrrolidone; and an adhesive layer, wherein the rate control membrane contains micropores formed by the dissolution of polyvinylpyrrolidone domains upon contact with biological fluids, and the arrangement of the laminated layers achieves sustained and sequential drug release through a combination of diffusion and erosion-mediated release mechanisms. [Effects of the Invention]

[0009] The disclosed structural configuration can enable sustained drug release over 24 to 168 hours. The multilayer configuration can reduce burst release characteristics compared to monolayer matrix systems. The use of nano-sized copolymer matrix sheets can facilitate encapsulation efficiencies exceeding 85 percent. An intermediate barrier layer allows for programming of sequential release phases with adjustable lag times. The rate-controlled membrane can provide near-zero-order drug release kinetics through diffusion via micropores. This device is biocompatible and biodegradable, making it suitable for transdermal, implantable, and mucosal drug delivery applications. [Brief explanation of the drawing]

[0010] [Figure 1] This is a schematic cross-sectional view of a multilayer drug delivery device (100) according to one embodiment of the present disclosure, showing the layered arrangement of a backing layer (101), a first nanosize copolymer matrix sheet (102), an intermediate barrier layer (103), a second nanosize copolymer matrix sheet (104), a rate control film (105), therapeutic agent particles (106), micropores (107), and an adhesive layer (108). [Modes for carrying out the invention]

[0011] Hereinafter, an embodiment of the multilayer drug delivery device (100) according to this disclosure will be described with reference to Figure 1.

[0012] The multilayer drug delivery device (100) comprises multiple functional layers arranged in a layered configuration. The device (100) includes a backing layer (101), a first nano-size copolymer matrix sheet (102), an intermediate barrier layer (103), a second nano-size copolymer matrix sheet (104), a rate control film (105), therapeutic agent particles (106), micropores (107), and an adhesive layer (108).

[0013] The backing layer (101) is the outermost layer of the device (100) and consists of an impermeable, biocompatible material selected from ethylene-vinyl acetate copolymer, polyethylene terephthalate, or polyurethane film, with a thickness of 50 to 200 micrometers. The backing layer (101) prevents drug loss from non-applicable surfaces, provides structural integrity to the device (100), and protects the internal drug-containing layer from environmental moisture and mechanical damage. The backing layer (101) is flexible and conforms to the biological surface.

[0014] The first nanoscale copolymer matrix sheet (102) is positioned adjacent to the backing layer (101) and functions as an independent drug reservoir and release control element. The first nanoscale copolymer matrix sheet (102) consists of a biodegradable block copolymer, specifically poly(lactic acid-glycolic acid copolymer)-block-polyethylene glycol (PLGA-PEG). This copolymer has a number-average molecular weight of 15,000 to 50,000 daltons, a polydispersity index of 1.2 to 1.5, and a lactic acid / glycolic acid molar ratio of 50:50 to 85:15. The first nanoscale copolymer matrix sheet (102) has a thickness in the range of 50 to 500 nanometers and a surface roughness of less than 10 nanometers. The first nanoscale copolymer matrix sheet (102) encapsulates therapeutic agent particles (106) within the nanoscale copolymer matrix through physical containment and molecular-level interactions between drug molecules and copolymer chains, achieving an encapsulation efficiency of over 85 percent.

[0015] An intermediate barrier layer (103) is placed between the first nano-sized copolymer matrix sheet (102) and the second nano-sized copolymer matrix sheet (104). The intermediate barrier layer (103) is made of a material selected from ethylcellulose, chitosan, or hydroxypropyl methylcellulose phthalate and has a thickness of 1 to 10 micrometers. The intermediate barrier layer (103) provides physical separation between adjacent drug-containing layers and controls drug diffusion. The ethylcellulose barrier provides a lag time of 6 to 24 hours due to its hydrophobicity and low water permeability, while the chitosan barrier provides a short lag time of 1 to 6 hours due to its pH-responsive swelling behavior. By varying the material and thickness of the barrier layer, the apparatus (100) can be programmed to sequentially deliver drugs with precise timing.

[0016] The second nano-sized copolymer matrix sheet (104) is positioned adjacent to the first nano-sized copolymer matrix sheet (102) on the opposite side of the intermediate barrier layer (103). The second nano-sized copolymer matrix sheet (104) has the same composition and structural characteristics as the first nano-sized copolymer matrix sheet (102) and independently encapsulates therapeutic agent particles (106). The second nano-sized copolymer matrix sheet (104) functions as a second drug reservoir that becomes accessible from the elution medium after the intermediate barrier layer (103) has degraded or become permeable.

[0017] The rate control membrane (105) is positioned adjacent to the second nano-sized copolymer matrix sheet (104) and comes into contact with the biological surface upon application. The rate control membrane (105) consists of a blend of ethylcellulose and polyvinylpyrrolidone in a weight ratio of 70:30 to 90:10 and has a thickness of 10 to 50 micrometers. The rate control membrane (105) contains micropores (107) with a diameter of 100 to 500 nanometers, formed by the dissolution of water-soluble polyvinylpyrrolidone domains upon contact with biological fluids. The micropores (107) function as channels for the therapeutic agent particles (106) to diffuse from the nano-sized copolymer matrix sheet (102, 104) into the surrounding biological environment at a controlled rate. The rate control membrane (105) ensures that the overall drug release follows a sustained, near-zero-order kinetic profile.

[0018] The adhesive layer (108) is applied to the outermost surface of the rate control membrane (105) for transdermal application. The adhesive layer (108) consists of a medical-grade acrylate-based pressure-sensitive adhesive with a thickness of 20-50 micrometers, providing secure adhesion to the skin while maintaining drug permeability.

[0019] The drug release mechanism from the device (100) includes three concurrent processes: diffusion of therapeutic agent particles (106) through nanoscale pores in the copolymer matrix sheets (102, 104), release via erosion that progressively increases the porosity of the matrix through hydrolytic degradation of the PLGA-PEG copolymer backbone, and barrier-modulated sequential release controlled by the intermediate barrier layer (103). The combined effects of these processes generate a drug release profile characterized by an initial phase of sustained diffusion-controlled release from the first nanosized copolymer matrix sheet (102), followed by programmed sequential release from the second nanosized copolymer matrix sheet (104) accompanying the degradation of the intermediate barrier layer (103).

[0020] The device (100) can be configured to include additional nanosized copolymer matrix sheets and corresponding intermediate barrier layers to achieve a multiphase release profile tailored to specific therapeutic requirements. [Industrial Applicability]

[0021] The multilayer drug delivery device (100) of the present disclosure is usable in the pharmaceutical industry and the medical device industry. The device (100) can be manufactured by a solvent casting method and a sequential lamination assembly technique, and is adaptable for transdermal, implantable, and mucosal delivery of analgesics, anti-inflammatory agents, antibacterial agents, or anticancer agents with reduced administration frequency. [Description of Symbols]

[0022] 100 Multilayer drug delivery device 101 Backing layer 102 First nanosized copolymer matrix sheet 103 Intermediate barrier layer 104 Second nanosized copolymer matrix sheet 105 Rate-controlling membrane 106 Therapeutic agent particles 107 Micropore 108 Adhesive layer

Claims

[Claim 1] A backing layer (101) made of an impermeable biocompatible material, A first nano-sized copolymer matrix sheet (102) is arranged adjacent to the backing layer (101), is made of poly(lactic acid-glycolic acid copolymer)-block-polyethylene glycol copolymer, has a thickness in the range of 50 to 500 nanometers, and encapsulates therapeutic agent particles (106). An intermediate barrier layer (103) is disposed adjacent to the first nano-sized copolymer matrix sheet (102), A second nanosize copolymer matrix sheet (104) is positioned adjacent to the first nanosize copolymer matrix sheet (102) in the intermediate barrier layer (103) on the opposite side, and encapsulates therapeutic agent particles (106). A rate control membrane (105) made of a blend of ethylcellulose and polyvinylpyrrolidone is positioned adjacent to the second nano-sized copolymer matrix sheet (104), An adhesive layer (108) is disposed on the outer surface of the speed control film (105), A multilayer drug delivery device (100) comprising, The speed control membrane (105) includes fine pores (107) with a diameter of 100 to 500 nanometers, which are formed by the dissolution of polyvinylpyrrolidone domains upon contact with biological fluid. The backing layer (101), the first nano-sized copolymer matrix sheet (102), the intermediate barrier layer (103), the second nano-sized copolymer matrix sheet (104), the rate control film (105), and the adhesive layer (108) cooperate in a laminated configuration to achieve sustained and sequential drug release through a combination of diffusion of the therapeutic agent particles (106) via the micropores (107) and degradation via erosion of the copolymer matrix. A multilayer drug delivery device characterized by the following features.

Citation Information

Patent Citations

  • Multilayer thin film drug delivery device and methods of making and using the same

    US10864158B2

  • Transdermal systems containing multilayer adhesive matrices to modify drug delivery

    US20120078204A1